News

Cerapedics to participate in Canaccord Genuity's Musculoskeletal Conference

Cerapedics receives FDA approval for i-FACTOR Peptide Enhanced Bone Graft in Cervical Spine Surgery

Orthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application

Cerapedics announces FDA Advisory Committee Panel Is not required for i-FACTOR PMA Approval

Orthobiologics company has submitted response to remaining items from PMA review of i-FACTOR Peptide Enhanced Bone Graft

Cerapedics announces closing of loan and equity financing

Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also a…

Study supports use of Cerapedics i-FACTOR Biologic Bone Graft as alternative to Autograft in common spine surgery for chronic back pain

Results published in International Journal of Spine Surgery

Cerapedics receives CE mark and TGA listing for new i-FACTOR™ Flex FR Biologic Bone Graft

Proven P-15 bone graft technology now features enhanced handling with addition of purified silk fibers

Novel i-FACTOR Biologic Bone Graft Shown to improve clinical outcomes in ALIF procedures

Results from the first prospective clinical study of i-FACTOR bone graft in anterior lumbar interbody fusion surgery published in the Journal of Neurosurgery: Spine

Cerapedics files premarket approval application with US FDA for i-FACTOR™ Peptide Enhanced Bone Graft

Application is supported by data from a pivotal clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in certain procedures

Cerapedics announces closing of venture debt loan from GE Capital

Cerapedics today announced closing of a $9 million venture debt financing from GE Capital, Healthcare Financial Services.

Cerapedics announces positive results from IDE clinical trial

Results provide significant support to advance i-FACTOR™ Peptide Enhanced Bone Graft for FDA regulatory review.